Harmony Biosciences Holdings, Inc. HRMY 深 滬
已收盤 04-02 16:00:00 美东时间
27.74
-0.220
-0.79%
華盛通- 最 高27.84
- 今 開27.44
- 成交量 52.38万股
- 最 低 27.2101
- 昨 收 27.96
- 總市值 16.04亿
- 52周最高 40.87
- 市盈率 靜 10.23
- 換手率 0.91%
- 52周最低 25.52
- 委 比 82.54%
- 總股本 5784.06万
- 歷史最高 62.085
- 量 比 0.76
- 振 幅 2.25%
- 歷史最低 18.6112
- 每 手 1
- 風險率 3.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harmony Biosciences Announces The Appointment Of Peter Anastasiou As Chief Operating Officer
Appointments support Harmony's next phase of growth and long‑term value creationHarmony Biosciences Holdings, Inc. (NASDAQ:HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates
04-02 20:11
Harmony Biosciences to Participate in Upcoming Investor Conferences in Miami
Harmony Biosciences to Participate in Upcoming Investor Conferences in Miami Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) said its management team will attend upcoming investor conferences in Miami, Florida: the Leerink Partners Global Healthcare Conference and the UBS Biotech Summit on March 9
03-04 21:05
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Needham Maintains Buy on Harmony Biosciences Hldgs, Lowers Price Target to $44
Needham analyst Ami Fadia maintains Harmony Biosciences Hldgs (NASDAQ:HRMY) with a Buy and lowers the price target from $46 to $44.
02-25 17:29
财报速睇 | Harmony Biosciences Holdings, Inc. 2025财年Q4营收2.44亿美元，同比增长21.1%；归母净利润0.22亿美元，同比下滑54.6%
华盛资讯2月24日讯，Harmony Biosciences Holdings, Inc.公布2025财年Q4业绩，公司Q4营收2.44亿美元，同比增长21.1%，归母净利润0.22亿美元，同比下滑54.6%。
02-24 21:34
Harmony Biosciences Q4 revenue beats estimates on WAKIX demand
Harmony Biosciences Q4 revenue beats estimates on WAKIX demand Overview Pharmaceutical company's Q4 revenue rose 21% yr/yr, beating analyst expectations Company reported Q4 pretax profit missed analyst estimates Outlook Harmony Biosciences reiterates 2026 WAKIX revenue guidance of $1.0 bln to $1.04
02-24 20:40
Harmony Biosciences Sees FY2026 Sales $1.000B-$1.040B vs $1.012B Est
2026 Net Product Revenue Guidance Reiterated 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04B
02-24 20:32
Harmony Biosciences Hldgs Earnings Review: Q4 Summary
The earnings results for Harmony Biosciences Hldgs (NASDAQ:HRMY) for Q4 were ma...
02-24 20:32
Harmony Biosciences Q4 Adj. EPS $0.57 Misses $0.90 Estimate, Sales $243.776M Beat $240.286M Estimate
Harmony Biosciences (NASDAQ:HRMY) reported quarterly earnings of $0.57 per share which missed the analyst consensus estimate of $0.90 by 36.74 percent. This is a 48.18 percent decrease over earnings of $1.10 per share
02-24 20:31
Earnings Scheduled For February 24, 2026
Companies Reporting Before The Bell • China Yuchai Intl (NYSE:CYD) is expected ...
02-24 19:11
